YMAB Accounts Payable vs Other Current Liab Analysis

YMAB Stock  USD 10.01  0.27  2.63%   
Y MAbs financial indicator trend analysis is more than just analyzing Y mAbs Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Y mAbs Therapeutics is a good investment. Please check the relationship between Y MAbs Accounts Payable and its Other Current Liab accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Accounts Payable vs Other Current Liab

Accounts Payable vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Y mAbs Therapeutics Accounts Payable account and Other Current Liab. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Y MAbs' Accounts Payable and Other Current Liab is 0.86. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Y mAbs Therapeutics, assuming nothing else is changed. The correlation between historical values of Y MAbs' Accounts Payable and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Y mAbs Therapeutics are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Accounts Payable i.e., Y MAbs' Accounts Payable and Other Current Liab go up and down completely randomly.

Correlation Coefficient

0.86
Relationship DirectionPositive 
Relationship StrengthStrong

Accounts Payable

An accounting item on the balance sheet that represents Y MAbs obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Y mAbs Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Current Liab

Most indicators from Y MAbs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Y mAbs Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
As of December 12, 2024, Selling General Administrative is expected to decline to about 33.2 M. In addition to that, Tax Provision is expected to decline to about 308.6 K
 2023 2024 (projected)
Depreciation And Amortization735K540.3K
Interest Income687.7K979.4K

Y MAbs fundamental ratios Correlations

0.740.831.00.430.99-0.96-0.710.870.980.980.890.560.780.630.850.880.860.821.00.890.45-0.270.870.830.73
0.740.960.680.660.71-0.59-0.960.860.610.610.90.910.830.810.970.840.970.960.710.90.42-0.40.470.380.62
0.830.960.770.680.78-0.7-0.920.960.730.730.910.890.760.790.950.920.971.00.80.910.51-0.310.570.490.76
1.00.680.770.371.0-0.98-0.660.830.990.990.860.490.760.580.80.840.820.761.00.860.43-0.250.890.860.7
0.430.660.680.370.39-0.29-0.720.560.330.330.680.720.580.90.680.780.680.740.390.680.16-0.310.120.050.72
0.990.710.781.00.39-0.96-0.680.810.980.980.880.510.80.620.830.850.840.780.990.880.42-0.280.880.840.69
-0.96-0.59-0.7-0.98-0.29-0.960.51-0.78-0.98-0.98-0.78-0.36-0.66-0.48-0.73-0.79-0.73-0.69-0.97-0.78-0.450.03-0.92-0.91-0.71
-0.71-0.96-0.92-0.66-0.72-0.680.51-0.82-0.59-0.59-0.89-0.93-0.82-0.85-0.92-0.84-0.95-0.94-0.68-0.9-0.30.61-0.39-0.3-0.6
0.870.860.960.830.560.81-0.78-0.820.810.810.850.770.660.630.860.890.890.940.850.850.52-0.20.650.590.76
0.980.610.730.990.330.98-0.98-0.590.811.00.810.420.690.520.740.820.760.720.990.810.43-0.20.90.880.7
0.980.610.730.990.330.98-0.98-0.590.811.00.810.420.690.520.740.820.760.720.990.810.43-0.20.90.880.7
0.890.90.910.860.680.88-0.78-0.890.850.810.810.790.930.860.970.910.970.930.871.00.31-0.390.620.550.73
0.560.910.890.490.720.51-0.36-0.930.770.420.420.790.660.830.850.760.860.90.520.790.42-0.470.280.190.65
0.780.830.760.760.580.8-0.66-0.820.660.690.690.930.660.780.880.750.870.790.760.930.16-0.530.460.390.47
0.630.810.790.580.90.62-0.48-0.850.630.520.520.860.830.780.860.860.850.840.590.860.26-0.430.370.290.77
0.850.970.950.80.680.83-0.73-0.920.860.740.740.970.850.880.860.910.990.970.820.960.41-0.330.610.530.72
0.880.840.920.840.780.85-0.79-0.840.890.820.820.910.760.750.860.910.930.940.860.910.48-0.280.680.620.89
0.860.970.970.820.680.84-0.73-0.950.890.760.760.970.860.870.850.990.930.980.830.970.4-0.390.610.530.72
0.820.961.00.760.740.78-0.69-0.940.940.720.720.930.90.790.840.970.940.980.790.930.49-0.330.550.480.78
1.00.710.81.00.390.99-0.97-0.680.850.990.990.870.520.760.590.820.860.830.790.870.45-0.240.880.850.72
0.890.90.910.860.680.88-0.78-0.90.850.810.811.00.790.930.860.960.910.970.930.870.3-0.430.620.550.72
0.450.420.510.430.160.42-0.45-0.30.520.430.430.310.420.160.260.410.480.40.490.450.30.110.540.520.56
-0.27-0.4-0.31-0.25-0.31-0.280.030.61-0.2-0.2-0.2-0.39-0.47-0.53-0.43-0.33-0.28-0.39-0.33-0.24-0.430.110.030.070.0
0.870.470.570.890.120.88-0.92-0.390.650.90.90.620.280.460.370.610.680.610.550.880.620.540.031.00.67
0.830.380.490.860.050.84-0.91-0.30.590.880.880.550.190.390.290.530.620.530.480.850.550.520.071.00.63
0.730.620.760.70.720.69-0.71-0.60.760.70.70.730.650.470.770.720.890.720.780.720.720.560.00.670.63
Click cells to compare fundamentals

Y MAbs Account Relationship Matchups

Y MAbs fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets216.4M132.0M212.8M141.5M127.9M150.1M
Other Current Liab4.6M6.2M10.8M12.4M12.3M7.2M
Total Current Liabilities13.6M19.5M27.9M28.3M20.1M17.8M
Total Stockholder Equity198.9M105.8M180.1M109.2M101.0M127.8M
Other Liab2.2M4.7M3.0M3.1M3.5M3.0M
Net Tangible Assets198.9M105.8M178.4M106.2M122.2M129.5M
Net Debt(204.9M)(110.7M)(177.9M)(104.0M)(77.2M)(81.1M)
Retained Earnings(165.9M)(285.2M)(340.5M)(436.0M)(457.5M)(434.6M)
Accounts Payable8.5M9.4M13.6M14.2M6.1M9.0M
Cash207.1M114.6M181.6M105.8M78.6M129.7M
Non Current Assets Total4.4M9.7M10.5M11.0M16.8M17.6M
Non Currrent Assets Other370K3.3M3.2M5.7M12.5M13.1M
Cash And Short Term Investments207.1M114.6M181.6M105.8M78.6M129.7M
Common Stock Shares Outstanding35.2M40.1M43.2M43.7M43.6M41.4M
Liabilities And Stockholders Equity216.4M132.0M212.8M141.5M127.9M150.1M
Non Current Liabilities Total3.9M6.7M4.8M4.0M6.8M4.5M
Capital Surpluse225.4M364.7M391.6M519.2M597.1M304.2M
Other Current Assets4.8M7.7M7.5M5.5M5.0M4.9M
Other Stockholder Equity364.7M391.6M519.2M543.9M558.0M379.6M
Total Liab17.5M26.2M32.7M32.2M26.9M22.3M
Total Current Assets212.0M122.4M202.3M130.4M111.1M142.8M
Accumulated Other Comprehensive Income50K(526K)1.4M1.3M449K349.7K
Other Assets370K7.9M206.9M5.7M1.00.95
Net Invested Capital198.9M105.8M180.1M109.2M101.0M104.9M
Net Working Capital198.4M102.8M174.4M102.2M91.0M102.2M
Property Plant And Equipment Net4.0M6.4M5.7M2.3M1.6M1.6M
Property Plant And Equipment Gross4.0M6.4M5.7M2.3M1.6M1.6M
Non Current Liabilities Other242K6.7M4.8M802K864K820.8K
Property Plant Equipment4.0M1.8M5.7M2.3M2.7M3.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.54)
Revenue Per Share
1.921
Quarterly Revenue Growth
(0.1)
Return On Assets
(0.12)
Return On Equity
(0.25)
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.